Skip to main content

Generics

  • Report: Lannett could be first company bankrupted amid drug price scrutiny

    LOS ANGELES — A new report from Citron Research is outlining why it expects Lannett to be the first pharmaceutical company to go bankrupt as a result of recent scrutiny on drug pricing. The analysis notes that Lannett is highly leveraged and dependent on three drugs for a bulk of its sales and that even modest price cuts to its biggest sellers would cause it to violate its debt covenants. 
     

  • New study: Growing share of drug prices go to rebates, supply chain

    WASHINGTON — A new study from the Berkeley Research Group is taking a look at the share of prescription drug spending that’s retained by biopharmaceutical companies, generics makers, pharmacy benefit managers, health plans and other supply chain stakeholders. 
     

  • Concerns over DIR fees top list of concerns for NCPA members

    ALEXANDRIA, Va. – Ensuring fair compensation and a level playing field are the chief concerns for community pharmacy operators as the 115th Congress begins their deliberations, according to the latest National Community Pharmacists Association member survey.

  • FDA issues draft guidance on biosimilar interchangeability

    SILVER SPRING, Md. — The Food and Drug Administration recently shared the first draft guidance addressing the interchangeability of biosimilar drugs and their reference products. 
     

  • Mayne Pharma launches generic Pacerone in new strength

    GREENVILLE, N.C. — Mayne Pharma on Monday announced the launch of its generic of Paceron (amiodarone) tablets in 100-mg dosage strength. The company had already launched the drug, which is indicated to treat recurrent ventricular arrhythmia, in 400-mg dosage strength. 
     

  • CVS introduces cheaper EpiPen competitor

    WOONSOCKET, R.I. — CVS introduced a generic version of injectable epinephrine to compete with Mylan’s EpiPen at all of its locations. The product carries a cash price of $109.99 for a two-pack.

  • Teva launches generic Lamictal XR in new strength

    NORTH WALES, Penn. — Teva Pharmaceuticals on Wednesday announced the launch of its generic of Lamictal XR (lamotrigine) extended-release tablets in 250-mg dosage strength. 
     
    The drug is indicated as an adjunctive therapy for patients older than 13 years of age with tonic-clonic seizure or partial-onset seizures with or without secondary generalization, and as monotherapy in patients older than 13 with partial onset seizures receiving treatment with a single AED. 
     

  • Teva launches generic Symmetrel

    NORTH WALES, Penn. — Teva Pharmaceuticals recently launched its generic of Symmetrel (amantadine hydrochloride). The drug is indicated to treat and prevent influenza A and as a treatment for parkinsonism and drug-induced extrapyramidal reactions. 
     
X
This ad will auto-close in 10 seconds